Blood pressure drug recalled because of cancer risk
The Food and Drug Administration has published information on its web site listing the blood pressure medicines that have been recalled because of their carcinogenicity. The following should be noted.
Macleods Pharmaceuticals Limited recalls 32 batches of the popular blood pressure drug Losartan after discovering traces of a likely carcinogen.
The recalled losartan and potassium / hydrochlorothiazide combination tablets contained low levels of N-nitrosodiethylamine or NDEA, according to a company announcement published Wednesday, by the Food and Drug Administration website.
"The active ingredient was manufactured by Hetero Labs Limited of India, one of the overseas drug factories," the recall notice has iterating repeated blood drug recalls since last July.
For the same reason, Macleods recalled a batch of the Losartan combination drug in February. The company stated in the statement that "no reports of adverse effects have been received for this recall".
Callback for MacBook Pro: Apple Voluntarily Retrieves Batteries from MacBook Pro Notebooks for Safety
Rock & Play Playback: Fisher- Price Recalls 4.7 Million Baby Sleepers After Reported Death Cited as a great plan to lower blood pressure, improve heart health and lose weight.
Health professionals advise patients to contact their physicians or pharmacists before they discontinue any of the recalled blood pressure medicines or seek alternative treatment.
Consumers who have any medical questions or need to report an adverse event can contact Macleods at 8:00 pm to 5:00 pm at 855-926-3384. EUROPEAN SUMMER TIME.
If you have any questions about returning the product, please contact Qualanex by email at email@example.com or by phone between 8:00 am and 4:00 pm, 888-280-2046. CST weekdays.
Has your medicine been recalled?
The doses, lot numbers and expiration dates of the recalled drug are listed here:
Losartan Potassium Tablets 50 mg:
- BL1711A, BL1710A, November 2019
Losartan Potassium and Hydrochlorothiazide Tablets 50 mg / 12 , BLK722A, BLK724A, September 2019
BLK725A, BLK726A, October 2019 [19659022A2020K80ABLK826AOctober2021
Losartan potassium and hydrochlorothiazide tablets 100 mg / 12.5 mg:
- BLM716A, BLM717A, July 2019
- BLM719A, BLM720A, August 2019
- BLM721A, BLM79022, BLM724A, BLM725A, October 2019
- BLM726A, November 2019
- BLM802A, BLM803A, December 2019  BLM825A, BLM826A, BLM827A, September 2021
Contribution: Ken Alltucker on Twitter  @KellyTyko
Read or Share This Story: h ttps: //www.usatoday.com/story/ money / 2019/06/26 / losartan-recall-2019-blood-pressure-drug-recalled -cancer-risk / 1578603001 /